Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma.
BACKGROUND:Estimation of the prognosis of resectable pancreatic ductal adenocarcinoma (PDAC) currently relies on tumour-related factors such as resection margins and on lymph-node ratio (LNR) both inconveniently available only postoperatively. Our aim was to assess the accuracy of preoperative labor...
Main Authors: | Aino Salmiheimo, Harri Mustonen, Ulf-Håkan Stenman, Pauli Puolakkainen, Esko Kemppainen, Hanna Seppänen, Caj Haglund |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5025052?pdf=render |
Similar Items
-
Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma
by: Anna M. Nurmi, et al.
Published: (2021-01-01) -
Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
by: Kapo Saukkonen, et al.
Published: (2015-01-01) -
Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma
by: Kapo Saukkonen, et al.
Published: (2018-03-01) -
Nuclear ubiquitin C-terminal hydrolase L5 expression associates with increased patient survival in pancreatic ductal adenocarcinoma
by: Leena Arpalahti, et al.
Published: (2017-06-01) -
Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival
by: Matilda Holm, et al.
Published: (2020-06-01)